{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:42:59Z","timestamp":1790419379794,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007497","name":"Biosense Webster","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["23HL143156"],"award-info":[{"award-number":["23HL143156"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL142913"],"award-info":[{"award-number":["R01 HL142913"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ahj.2021.08.013","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T01:07:55Z","timestamp":1631840875000},"page":"127-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease"],"prefix":"10.1016","volume":"243","author":[{"given":"Tyson S.","family":"Burnham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi T.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami L.","family":"Bair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Crandall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-4130","authenticated-orcid":false,"given":"Kirk U.","family":"Knowlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Muhlestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leenhapong","family":"Navaravong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi A.","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4729-7820","authenticated-orcid":false,"given":"Benjamin A.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5349-0136","authenticated-orcid":false,"given":"T. Jared","family":"Bunch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2021.08.013_bib0001","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.08.013_bib0002","doi-asserted-by":"crossref","first-page":"488","DOI":"10.5694\/j.1326-5377.1992.tb126477.x","article-title":"Treatment of ventricular arrhythmias after CAST","volume":"156","author":"Tonkin","year":"1992","journal-title":"Med J Aust"},{"key":"10.1016\/j.ahj.2021.08.013_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9149(84)90509-5","article-title":"Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram","volume":"53","author":"Morganroth","year":"1984","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2021.08.013_bib0004","first-page":"181","article-title":"Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction","volume":"35","author":"Lynch","year":"1987","journal-title":"Pharmacology"},{"key":"10.1016\/j.ahj.2021.08.013_bib0005","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1161\/01.CIR.90.6.2843","article-title":"Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST)","volume":"90","author":"Anderson","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.08.013_bib0006","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2018.05.026","article-title":"Evaluation of cardiac arrhythmic risks using a rabbit model of left ventricular systolic dysfunction","volume":"832","author":"Hemmeryckx","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ahj.2021.08.013_bib0007","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/bph.13807","article-title":"Multiple targets for flecainide action: implications for cardiac arrhythmogenesis","volume":"175","author":"Salvage","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ahj.2021.08.013_bib0008","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1055\/s-2008-1068315","volume":"112","author":"Nitsch","year":"1987","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.ahj.2021.08.013_bib0009","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/BF01856514","article-title":"Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone","volume":"4","author":"Leclercq","year":"1990","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ahj.2021.08.013_bib0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v7.i2.76","article-title":"Current status and perspectives in arrhythmia management","volume":"7","author":"Andrikopoulos","year":"2015","journal-title":"World J Cardiol"},{"key":"10.1016\/j.ahj.2021.08.013_bib0011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.vascn.2018.06.001","article-title":"Decreased contractility and altered responses to inotropic agents in myocytes from tachypacing-induced heart failure canines","volume":"93","author":"Gao","year":"2018","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.ahj.2021.08.013_bib0012","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0002-8703(85)90557-5","article-title":"Efficacy of flecainide in the management of ventricular arrhythmias: comparative study with amiodarone","volume":"109","author":"Dubner","year":"1985","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2021.08.013_bib0013","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0002-9149(99)80655-9","article-title":"Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation","volume":"75","author":"Donovan","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2021.08.013_bib0014","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S0002-9149(98)00223-9","article-title":"Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation","volume":"81","author":"Reisinger","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2021.08.013_bib0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s11739-016-1497-4","article-title":"Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs","volume":"12","author":"Bonora","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.ahj.2021.08.013_bib0016","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ahj.2018.06.018","article-title":"Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs","volume":"205","author":"Friberg","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2021.08.013_bib0017","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jacep.2018.08.025","article-title":"Real-World Comparison of Classes IC and III Antiarrhythmic Drugs as an Initial Rhythm Control Strategy in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study","volume":"5","author":"Kipp","year":"2019","journal-title":"JACC Clin Electrophysiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321002118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321002118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:42:08Z","timestamp":1778640128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870321002118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":17,"alternative-id":["S0002870321002118"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2021.08.013","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2021.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}